AMETEK, Inc. (AME) Stock Price & How to Invest

AMETEK is a Berwyn, Pennsylvania manufacturer of electronic instruments and electromechanical devices, founded in 1930 and employing roughly 22,500 people. It runs two segments. The Electronic Instruments Group (EIG) builds analytical, test and measurement, process and aerospace instrumentation, including power quality monitors, materials analysis systems and cockpit sensors. The Electromechanical Group (EMG) makes engineered electrical connectors and interconnects, precision motion components, thermal management products and, since the Paragon Medical acquisition, contract-manufactured medical instruments and implantable components. The common thread is niche leadership: AMETEK deliberately targets small, differentiated product categories where it can hold a top position and price for engineering content rather than compete on volume.

The business model is as much capital allocation as manufacturing. AMETEK has bought hundreds of businesses over decades, layering them onto a decentralized operating system and pulling margins up through its internal operational excellence program. That shows in the numbers: operating margin near 26 percent, profit margin around 20 percent, and free cash flow of roughly $1.8 billion on about $7.9 billion of trailing revenue. Q2 2026 was a record quarter, with sales up about 15 percent to roughly $2.04 billion, adjusted EPS of about $2.09, orders up about 28 percent to a record $2.3 billion and backlog near $4.11 billion. Management raised 2026 adjusted EPS guidance to roughly $8.20 to $8.30 and has a $5 billion purchase of Indicor's instrumentation portfolio expected to close in the second half. The counterweight is valuation: at roughly $254 per share and a $58 billion market cap, the stock trades near the top of its historical range.

Valuation is the most immediate risk: at roughly 37 times trailing and about 29 times forward earnings, with an EV/EBITDA near 24, the shares price in continued execution and leave limited room for a demand air pocket. The Indicor deal carries integration and leverage risk at a size AMETEK has not attempted before, and cost synergies of 10 to 12 percent are a target rather than a result. Roughly half of sales come from outside the United States, exposing results to currency, tariffs and global capital spending cycles, while short-cycle instrument orders can turn quickly if industrial demand cools. AI infrastructure and defense are currently strong contributors and would become concentration risks if either budget cycle reversed. Separately, AMETEK carries long-running environmental and toxic tort litigation related to groundwater contamination from a former subsidiary site in El Cajon, California, an ordinary-course legal exposure disclosed in its filings; no active securities-fraud class action was identified against the company as of August 2026.

18 analysts publish price targets on AME, averaging $277.22 against a $253.66 price as of August 2026, or +9.3%. The published targets run from $217.00 to $316.00, a moderate spread, and the ratings split 14 buy, 5 hold, 1 sell. Over the last six months there have been 10 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full AME forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on AMETEK, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Record orders tied to AI infrastructure, aerospace and defense. Q2 2026 orders rose about 28 percent to a record $2.3 billion, lifting backlog to roughly $4.11 billion. The most optimistic published target, $316.00, assumes this works close to its best case.

The case against. Valuation is the most immediate risk: at roughly 37 times trailing and about 29 times forward earnings, with an EV/EBITDA near 24, the shares price in continued execution and leave limited room for a demand air pocket. The most pessimistic target, $217.00, is roughly what AME is worth if this bites instead.

Read the full bull and bear case on AME, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see AMETEK, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$7.86B, up ~12.7%
• Net income (TTM): ~$1.58B (~20% margin)
• Q2 2026 sales / adj. EPS: ~$2.04B (+15%) / ~$2.09
• 2026 adj. EPS guidance: ~$8.20 to $8.30
• Market cap: ~$58B at ~$254 per share
• P/E trailing / forward: ~37 / ~29

AMETEK trades at a clear premium to the broader industrial group, with a trailing P/E near 37, a forward P/E near 29 and EV/EBITDA around 24. The premium reflects roughly 26 percent operating margins, about $1.8 billion of free cash flow and a long record of accretive acquisitions rather than unusual top-line growth. The shares were near $254 in early August 2026 against a 52-week range of roughly $179 to $258, so recent record results and the raised guidance are largely reflected in the price.

Other names that sit close to AME: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get AME exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so AME sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where AME fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

AME is a disciplined niche-instruments compounder with record backlog and a $5 billion acquisition in flight, where the debate is whether the growth reacceleration justifies a high-30s trailing earnings multiple.

Whether AME is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is AME a buy or a sell?, and where the stock could go from here in the AME stock forecast.

For income investors, whether AME pays a dividend and how the payout looks is covered in does AME pay a dividend? And to weigh AME against a peer, read the full side-by-side comparisons: AME vs FTV and AME vs ROP.